• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Boundless Bio Inc (NQ: BOLD )

    3.620 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 3.620
    Bid (Size) 1.470 (1)
    Ask (Size) 4.250 (5)
    Prev. Close 3.620
    Today's Range 3.620 - 3.620
    52wk Range 2.850 - 14.72
    Shares Outstanding 45,783,265
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
    BOLD stock results show that Boundless Bio beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
    From Boundless Bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -74.60%
    -74.60%
    1 Month
    +20.67%
    +20.67%
    3 Month
    -60.13%
    -60.13%
    6 Month
    -74.60%
    -74.60%
    1 Year
    -74.60%
    -74.60%

    More News

    Read More
    Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Boundless Bio
    Via Business Wire
    BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024
    Via InvestorPlace
    Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
    From Boundless Bio
    Via Business Wire
    Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
    From Boundless Bio
    Via Business Wire
    Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
    From Boundless Bio
    Via Business Wire
    Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
    From Boundless Bio
    Via Business Wire
    Bayer-Backed Boundless Bio Falls After IPO
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.